The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
The influence on survival of delay in the presentation and treatment of symptomatic breast cancer
Open accessAbstract
The aim of this study was to examine the possible influence on survival of delays prior to presentation and/or treatment among women with breast cancer. Duration of symptoms prior to hospital referral was recorded for 2964 women who presented with any stage of breast cancer to Guy's Hospital between 1975 and 1990. Median follow-up is 12.5 years. The impact of delay (defined as having symptoms for 12 or more weeks) on survival was measured from the date of diagnosis and from the date when the patient first noticed symptoms to control for lead-time bias. Thirty-two per cent (942/2964) of patients had symptoms for 12 or more weeks before their first hospital visit and 32% (302/942) of patients with delays of 12 or more weeks had locally advanced or metastatic disease, compared with only 10% (210/2022) of those with delays of less than 12 weeks (P < 0.0001). Survival measured both from the date of diagnosis (P < 0.001) and from the onset of the patient's symptoms (P = 0.003) was worse among women with longer delays. Ten years after the onset of symptoms, survival was 52% for women with delays less than 12 weeks and 47% for those with longer delays. At 20 years the survival rates were 34% and 24% respectively. Furthermore, patients with delays of 12-26 weeks had significantly worse survival rates than those with delays of less than 12 weeks. Multivariate analyses indicated that the adverse impact of delay in presentation on survival was attributable to an association between longer delays and more advanced stage. However, within individual stages, longer delay had no adverse impact on survival. Analyses based on 'total delay (i.e. the interval between a patient first noticing symptoms and starting treatment) yielded very similar results in terms of survival to those based on delay to first hospital visit (delay in presentation).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bloom, H. J. G., & Richardson, W. W. (1957) · British Journal of Cancer · doi:10.1038/bjc.1957.43 · Cited by 2,925
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
Early Breast Cancer Trialist's Collaborative Group (1992) · The Lancet · doi:10.1016/0140-6736(92)90997-h · Cited by 2,182
TORULOPSIS GLABRATA SEPTICqMIA TREATED WITH 5-FLUOROCYTOSINE
WEBB, A. (1970) · The Lancet · doi:10.1016/s0140-6736(70)92438-4 · Cited by 367
Who and what influences delayed presentation in breast cancer?
Burgess, C., Ramirez, A., Richards, M., & Love, S. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.224 · Cited by 240
Self-citationFacione, N. C. (1993) · Social Science & Medicine · doi:10.1016/0277-9536(93)90340-a · Cited by 235
SCOTTISHCANCERTRIALSBREASTGROU (1993) · The Lancet · doi:10.1016/0140-6736(93)90812-u · Cited by 191
Stage and delay in breast cancer diagnosis by race, socioeconomic status, age and year
Richardson, J., Langholz, B., Bernstein, L., Burciaga, C., Danley, K., & Ross, R. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.193 · Cited by 188
The Relative Significance of Prognostic Factors in Breast Carcinoma
Alderson, M., Hamlin, I., & Staunton, M. D. (1971) · British Journal of Cancer · doi:10.1038/bjc.1971.80 · Cited by 96
Medicolegal Analysis of the Delayed Diagnosis of Cancer in 338 Cases in the United States
Kern, K. A. (1994) · Archives of Surgery · doi:10.1001/archsurg.1994.01420280073009 · Cited by 64
Prognostic Factors in Mammary Carcinoma
Wallgren, A., Silfverswärd, C., & EKLUND, G. A. (1976) · Acta Radiologica Therapy Physics Biology · doi:10.3109/02841867609132703 · Cited by 58
Cited by
Origins of socio-economic inequalities in cancer survival: a review
Woods, L. M., Rachet, B., & Coleman, M. P. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj007 · Cited by 1,106
Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic
Sud, A., Jones, M. E., Broggio, J., Loveday, C., Torr, B., Garrett, A., Nicol, D. L., Jhanji, S., Boyce, S. A., Gronthoud, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.009 · Cited by 552
Macleod, U., Mitchell, E. D., Burgess, C., Macdonald, S., & Ramirez, A. J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605398 · Cited by 525
Self-citationPlanning cancer control in Latin America and the Caribbean
Goss, P. E., Lee, B. L., Badovinac-Crnjevic, T., Strasser-Weippl, K., Chavarri-Guerra, Y., Louis, J. S., Villarreal-Garza, C., Unger-Saldaña, K., Ferreyra, M., Debiasi, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70048-2 · Cited by 499
Sud, A., Torr, B., Jones, M. E., Broggio, J., Scott, S., Loveday, C., Garrett, A., Gronthoud, F., Nicol, D. L., Jhanji, S., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30392-2 · Cited by 484
Metadata
- Authors
- Richards, M. A., Smith, P., Ramirez, A. J., Fentiman, I. S., & Rubens, R. D.
- Venue
- British Journal of Cancer
- Published
- 1999-01-29
- Volume
- 79
- Issue
- 5-6
- Pages
- 858-864
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1981190419
- Cited by
- 277
- References
- 11
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. https://app.cochat.ai/papers/10.1038/sj.bjc.6690137
- The paper
- Richards, M. A., Smith, P., Ramirez, A. J., Fentiman, I. S., & Rubens, R. D. (1999). The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6690137
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.